A long-acting, mono-PEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats.
Recombinant human GH is used to treat GH deficiency in children and adults and wasting in AIDS patients. GH has a circulating half-life of only a few hours in humans and must be administered to patients by daily injection for maximum effectiveness. Previous studies showed that longer-acting forms of GH could be created by modification of GH with multiple 5-kDa amine-reactive polyethylene glycols (PEGs). Eight of nine lysine residues and the N-terminal amino acid were modified to varying extents by amine PEGylation of GH. The amine-PEGylated GH product comprised a complex mixture of multiple PEGylated species that differed from one another in mass, in vitro bioactivity, and in vivo potency. In vitro bioactivity of GH was reduced 100- to 1000-fold by extensive amine PEGylation of the protein. Here we describe a homogeneously modified, mono-PEGylated GH protein that possesses near complete in vitro bioactivity, a long half-life, and increased potency in vivo. The mono-PEGylated GH was created by substituting cysteine for threonine-3 (T3C) of GH, followed by modification of the added cysteine residue with a single 20-kDa cysteine-reactive PEG. The PEG-T3C protein has an approximate 8-fold longer half-life than GH after sc administration to rats. Every other day or every third day administration of PEG-T3C stimulates increases in body weight and tibial epiphysis growth comparable with that produced by daily administration of GH in hypophysectomized rats. Long-acting, mono-PEGylated GH analogs such as PEG-T3C are promising candidates for future testing in humans.
Cox
George N
GN
Bolder BioTechnology, Inc., 2945 Wilderness Place, Boulder, Colorado 80301, USA. jcox@bolderbio.com
Rosendahl
Mary S
MS
Chlipala
Elizabeth A
EA
Smith
Darin J
DJ
Carlson
Sharon J
SJ
Doherty
Daniel H
DH
D000818:Animals; D001846:Bone Development / Q000187:drug effects*; D003692:Delayed-Action Preparations; D004353:Drug Evaluation, Preclinical; D006207:Half-Life; D019382:Human Growth Hormone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics*; D007016:Hypophysectomy; D008297:Male; D011092:Polyethylene Glycols / Q000737:chemistry / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D013977:Tibia / Q000187:drug effects; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects*
D003692:Delayed-Action Preparations; D019382:Human Growth Hormone; D011092:Polyethylene Glycols